Patent · US Active

Optimized lentiviral transfer vectors and uses thereof

US11866725B2 · kind B2 · utility

0Cited by

1References

27Claims

0Family size

Assignees

Novartis AG · CH
The Trustees of the University of Pennsylvania · US

Inventors

Vladimir Slepushkin · Everett, US
Dmitriy LUKASHEV · Ashland, US

Key dates

Filing date	Nov 23, 2021
Grant date	Jan 9, 2024
Priority date	—
Expiry date	Nov 23, 2041

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2740/16043
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

The invention features lentiviral transfer vectors that include heterologous nucleic acids to be introduced into a cell. The lentiviral transfer vector may be characterized by the following features: (a) including a cytomegalovirus (CMV) promoter; (b) including a polynucleotide encoding a partial gag protein that includes a mutated INS1 inhibitory sequence that reduces restriction of nuclear export of RNA; (c) not including a polynucleotide encoding the INS2, INS3, and INS4 inhibitory sequences of gag; (d) not including an SV40 origin of replication and/or an f1 origin of replication; (e) including a cPPT sequence that contains splice site; (f) including an EF1alpha promoter with intact splice donor and acceptor sites; and (g) including hepatitis B PRE with mutation in start codon of X protein ORF.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.